Esperion Therapeutics Inc... (ESPR)
NASDAQ: ESPR
· Real-Time Price · USD
0.86
0.06 (7.26%)
At close: May 19, 2025, 3:59 PM
0.83
-3.36%
After-hours: May 19, 2025, 05:20 PM EDT
Company Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 26, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 304 |
| CEO | Sheldon L. Koenig |
Contact Details
Address: 3891 Ranchero Drive Ann Arbor, Michigan United States | |
| Website | https://www.esperion.com |
Stock Details
| Ticker Symbol | ESPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434868 |
| CUSIP Number | 29664W105 |
| ISIN Number | US29664W1053 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sheldon L. Koenig | President, Chief Executive Officer & Director |
| Benjamin Halladay M.B.A. | Chief Financial Officer |
| Benjamin O. Looker J.D. | General Counsel & Corporate Secretary |
| Betty Jean Swartz | Chief Business Officer |
| Dr. Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development |
| Glenn P. Brame | Chief Technical Operations Officer |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 08, 2025 | 10-Q | Quarterly Report |
| May 06, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 424B5 | Filing |
| Apr 21, 2025 | 4 | Filing |
| Apr 21, 2025 | 4 | Filing |
| Apr 18, 2025 | S-3 | Filing |
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | DEFA14A | Filing |
| Apr 17, 2025 | DEF 14A | Filing |
| Apr 07, 2025 | SCHEDULE 13G/A | [Amend] Filing |